Products

TurboReader™ Point-of-Care Instrument

The TurboReader™ is a compact, user-friendly diagnostic reader which together with single-use reagent cuvettes performs one analysis within minutes. The system can be operated with minimal training and performs tests on serum, plasma or whole blood. Automatic tests results are provided on a touch screen color display with the precision and accuracy comparable to a routine clinical chemistry analyzer found in the central laboratory.

Specifications:
Time to Result:Test dependent
Sample Throughput:Up to 15 samples/hour
Data Input:Barcode reader compatibility. Touch-screen. External data input capability
Data Output:Color display. External printer compatibility. External data output capability
Testing:Multiple tests performed on single instrument
Size: Height: 11.5 cm, Depth: 13.5 cm, Width: 21.5 cm
Weight: 1 kg
Voltage Requirements: 100-240V 50/60 Hz

Art. No. 2200-04.

TurboReader™ Reagent Assays

Canine CRP TurboReader™ Assay

This is an in vitro immunonephelometric assay for the quantitative determination of Canine C-Reactive (CRP) in dog serum or plasma. Canine CRP is real-time marker for systemic inflammation and infection, as well as, response to ongoing clinical treatment. Normal serum concentrations in healthy dogs is well below 35 mg/l.

Assay Principle: The rapid measuring procedure involves the pipetting of 20 µl of sample into a cuvette containing reaction buffer R1. After 1 minute, 3 drops of reaction buffer R2 are added. The quantitative result is presented within 3 minutes on the touch screen color display.

Kit Components:
Test Cuvettes (20 pcs.)
Dropper Bottle R2 (1 * 3.0 ml)
cCRP Level 2 Control (1 * 0.05 ml)

Art. No. 2530-01.

eurisTest™ for Clinical Analyzers

eurisTest™ Canine CRP Immunoturbidimetric Assay

This test is an immunoturbidimetric assay for the quantitative, in vitro determination of Canine of Canine C-Reactive (CRP) in dog plasma or serum, which can be a useful tool for monitoring systemic inflammation and managing ongoing clinical treatment.


Assay Principle: Mix 200 µl R1 assay buffer with 15 µl Sample (S) and let incubate for 5 minutes at 37 °C. Read the Absorbance (A1). After addition of 40 µl R2 antibody reagent mix and incubate for 5 minutes at 37 °C. Read the Absorbance (A2). Calculate ΔA = A2 - A1.

Kit Components:
R1 Assay Buffer (1 * 20 ml)
R2 Antibody Reagent (1 * 4.0 ml)
cCRP CAL200 Calibrator (1 * 0.5 ml)
cCRP Level 2 Control (1 * 1.0 ml)

Art. No. 2510-02.

eurisTest™ Lateral Flow Assays

eurisTest™ Canine CRP Lateral Flow Assay

This is for the rapid qualitative determination of Canine of Canine C-Reactive (CRP) in dog whole blood, plasma or serum. Repetitive measurements of Canine CRP can be a useful tool for monitoring systemic inflammation or ongoing treatment. A positive result suggests the concentration of Canine CRP in the sample is above the clinically acceptable threshold. A negative result suggests the concentration of Canine CRP in the sample is within the clinically acceptable range.


Assay Principle: Transfer dog sample (2.5 µl whole blood or 5 µl serum/plasma) to the sample well of the lateral flow test cassette. Drop lateral flow buffer into the sample well. Wait 5 minutes and then read the result.

Kit Components:
Lateral Flow Test Cassettes (10 units)
Lateral Flow Buffer (10x 2 ml)

Art. No. 2520-01.


ScheBo ® Pancreas Elastase 1 Quick™ Canine Test

This is a visual lateral flow assay for detecting canine pancreatic elastase1 in stool samples for noninvasive exocrine pancreatic function testing. This test allows for the fast and reliable diagnosis or exclusion of Exocrine Pancreatic Insufficiency (EPI). EPI is often underdiagnosed. The presenting symptoms are non-specific and may include: Weight loss, Maldigestion, Diarrhea, Vomiting and Poor coat condition. However, once diagnosed it can successfully be treated with pancreatic enzymes. A positive or “normal” result indicates normal exocrine pancreatic function. A negative or “low” result indicates exocrine pancreatic insufficiency (EPI).


Assay Principle: Collect dog stool sample using stool extraction system provided with the kit. Wait 10 minutes. Using the pipette, add 4 drops stool sample extract to the sample well of the lateral flow test cassette. Wait 10 minutes and then read the result.

Kit Components:
Ready-to-use Stool Extraction System (5x)
Pipette (5x)
Lateral Flow Test Cassette (5x)

Art. No. SCH-25-I.

Molecular and Other Veterinary Diagnostics

Genesig® q16 PCR Instrumentation

This is a quantitative PCR instrument for molecular veterinary diagnostics manufactured by Primerdesign®. The q16 can test up to 16 samples at a time and is designed to make DNA testing affordable and easy for veterinary health care.

Specifications:
Sampling: 16 wells, 20 ul reaction volume
PCR: Peltier thermal control. 3°C/s heating, 2°C/s cooling. Thermal uniformity +/- 0.1°C range. Thermal accuracy +/- 0.25°C
Multiplex Targets: LED excitation. CMOS detection. Multiplex detection. Internal control via FAM & VIC channels
Size: Height: 16 cm, Diameter: 12 cm, and weight: 2 kg
Power Consumption: 90 Watts
Key Features: Portable. Operate from PC, Mac, via network or USB drive. Excellent well-to-well reproducibility. Automated data calling

Product range:
Companion Animals: Detect FIV in cats, CDV in dogs, Infuenza in birds etc.
Farm Animals: Screen for Foot & Mouth or Blue Tongue outbreak.
Equine: Sexually transmitted diseases, Taylorella equigenitalis, Klebsella and P. Aeruginosa.

Art. No. 2210-01.


ScheBo® Pancreas Elastase 1 Canine ELISA Test

This is a quantitative, non-isotopic test for detecting canine pancreatic elastase1 in dog stool samples for noninvasive exocrine pancreatic function testing. This ELISA allows for the diagnosis or exclusion of exocrine pancreatic insufficiency (EPI) caused by, for example, pancreatic acinar atrophy, pancreatic tumor, chronic pancreatitis, parasites or stones. EPI is often underdiagnosed, but can be successfully treated with pancreatic enzymes. Values above 40 µg/g feces indicate normal pancreatic exocrine function. Values below 10 µg/g feces indicate a severe pancreatic exocrine insufficiency. Borderline values (“grey zone”) of 10 – 40 µg/g feces suggest the beginning of pancreatic exocrine insufficiency.


Assay Principle: Sandwich ELISA (96-well format) based on two monoclonal antibodies highly specific for canine pancreatic elastase 1.

Art. No. SCH-09.

About Us

The European Institute of Science AB is a manufacturer of diagnostic assays for the clinical laboratory and point-of-care settings, as well as, point-of-care instrumentation for diagnostic applications. Our mission is to provide veterinary and medical professionals with high-quality and accurate diagnostic tests and point-of-care instrumentation required for health care needs.

With a strong focus on veterinary health, the company’s primary focus is diagnostic assays and instrumentation for canine, feline and equine animals. In order to provide a complete veterinary product line, the European Institute of Science AB is also a distributor within Scandinavia for veterinary diagnostic products produced by external manufacturers.

The European Institute of Science AB has been a unique center of excellence within innovation and entrepreneurship for more than 25 years. Together with public financing provided by the company’s shareholders, the Institute has been able to create and develop more than ten high-tech patent families and the following four public companies: Biotech-IgG/Chemel AB (founded 1996), Genovis AB (founded 1999), Implementa Hebe AB (founded 2000) and LifeAssays AB (founded 2000). The company is situated at the IDEON research park in Lund, Sweden where it has a sales office and research facilities. Additionally, the company has production facilities near the international airport Kastrup in Denmark.

Quality Policy

The management at the European Institute of Science AB is committed to maintaining a comprehensive Quality System for the development, production and sales of safe & effective, high-quality diagnostic products. We achieve our commitment to quality by complying with all applicable regulatory requirements and by striving towards continuous improvement and high customer satisfaction.

Investors

Se presentationsfilm från Investeringsdagen: EURIS 2017-08-28

The European Institute of Science Inc. is a public shareholding company, which has been in existence for more than 25 years. Inventor & founder,dr. Dario Kriz, started the company in Malmoe, Sweden during 1990 with the core business centered around subcontracting and resale of laboratory equipment to chemical laboratories. During the first five years, the Institute built-up a mechanical & electronic workshop and a broad international network of subcontractors. A standard of professional craftsmanship was developed which is evident in today’s prototype constructions.

During 1994 the Institute established itself in the Science park IDEON (Lund, Sweden). This transfer of the activities from the location in Malmoe showed to be a strategically very successful step. Almost instantaneously, the Institute was carried along in a wave of intensive high-tech research resulting in several unique products. Today, four different off-spring companies have been created around medical and biotechnical products developed within the Institute’s research facilities.

The Institute went public during the fall of 1998 by conducting a public share issue in Sweden. The raised capital was used to help establish the European Institute of Science as a center of excellence in medical & biotechnology seen today. The know-how which has been built-up in the company since its foundation is currently used to create a new type of private incubator concept for technological projects. The core business idea is to provide soft capital in the form of research & prototype facilities as well as company know-how in economics and business management to early stage projects. In return, the Institute becomes part owners in the newly formed companies.

The Institute has had cofounded four different high-tech companies: Biotech-IgG AB (Chemel AB), Genovis AB, Implementa Hebe AB, and LifeAssays AB.

dr. Lars-Olof Hansson

dr. Lars-Olof Hansson, born in 1944, is the Chairman since 2004. He became M.D. in 1977, specialist in clinical chemistry in 1984, Ph.D. in medicine in 1996, and associate professor in 1998. He was previously the Head of the department of Clinical chemistry and pharmacology at the Academic Hospital in Uppsala (Sweden). He has over 50 scientific publications. He holds 54 516 shares of class B in European Institute of Science AB. Personal homepage: www.linkedin.com

dr. Dario Kriz

dr. Dario Kriz, born in 1965, is the president and board member since 1990. He became Ph.D. in Biochemistry in 1994, visiting professor at the University of Regensburg (Germany) during 1997-1998, associate professor in 2004, and Honorary Consul for Republic of Slovenia to Kingdom of Sweden in 2015. He is the inventor of several products and methods in medical technology and biotechnology. He has 25 scientific publications and 13 approved patents. He has been CEO, chairman and board member of several stock listed companies. He holds 264 000 shares of class A and 439,653 shares of class B in European Institute of Science AB. Personal homepage: www.linkedin.com

dr. Kirstin Kriz

dr. Kirstin Kriz, born in 1975, is a board member since 2004. She became B.S. (University of California, San Diego, USA) in 1996, and Ph.D. in Biochemistry in 2003. Dr. Kriz has been awarded with several prestigious distinctions such as UCSD Regents Scholarship in 1995, UCSD Undergraduate Scholarship in 1996, and Phi Beta Kappa lifetime membership in 1997 for her academic achievements at the University of California San Diego, UCSD. She has 7 scientific publications. She holds 264 000 shares of class A and 78,128 shares of class B in European Institute of Science AB.

dr. Arne Jakobsson

dr. Arne Jakobsson, born in 1945, is a board member since 2014. He received his Ph.D. in 1980 (Lunds Universitet). He has 6 scientific publications. Dr. Jakobsson worked 25 years as medical doctor and was head of Vårdcentralen Södertull during the period 2000-2008. He is currently the boardmember of Implementa Hebe AB (since 2011). Dr. Jakobsson was a boardmember of the stock company LifeAssays AB (during 2002-2010, and acted as chairman during 2003-2010). He has no shares in European Institute of Science AB.

Since 1997, European Institute of Science has been involved in developing industrial and laboratory small molecule and IgG analysis systems for the company Biotech-IgG (previously Chemel) AB, Lund (Sweden). Our success record in this particular case involved the securing of funding in the amount of approximately 10 million USD, development of 3 different patent families (instruments and procedures), acquiring EMC certification for instruments, and finally launching the products on the laboratory market. In 2009, the company acquired a Danish diagnostic kit distribution company group and thereby gained access to a professional sales organization with a net annual sales of approximately 2 million USD. Since 2011, European Institute of Science AB has engaged in assisting Biotech-IgG AB to expand its business into immunodiagnostics. Click here to visit the Biotech-IgG homepage.

During the period 2000 to February 2011, European Institute of Science has been involved in developing a new Point-of-Care blood analysis system for the company LifeAssays AB, Lund (Sweden). Our success record in this particular case involved the securing of funding in the amount of approximately 10 million USD, development of 7 different patent families (instrument, reagents and locked reagent data processing), acquiring EMC & ISO certification and environmental regulation permit, preparing for human IVD-CE registration (which was obtained in June 2011), and finally launching the product on the veterinary market. The product has been used to help several thousands of dog patients and reduced the unnecessary use of antibiotics for non-bacterial infections. At the end of 2010 LifeAssays had stable and growing production and sales levels, which led to the entry of the Swedish industrialist Sten K Johnsson who acquired the majority of the shares in LifeAssays. Click here to visit the LifeAssays homepage.

Since 2000, European Institute of Science has been involved in developing laboratory magnetic stirrers with cooling and heating capabilities for the company Implementa Hebe AB, Lund (Sweden). Our success record in this particular case involved the securing of funding in the amount of approximately 0,7 million USD, development of 3 different patent families (instruments and magnetic particles), acquiring EMC certification for instruments, and finally launching the products on the laboratory market. In 2010, the company acquired a patent portfolio from European Institute of Science (magnetic field generator and magnetic peptide nanoparticles) intended for therapeutic applications. Click here to visit the Implementa Hebe homepage.

During the period 1999 to 2005, European Institute of Science has been involved in developing a new gene transfer system for the company Genovis AB, Lund (Sweden). Our success record in this particular case involved the securing of funding in the amount of approximately 2 million USD, development of 3 different patent families and design of the instrument and magnetic nanoparticles. In 2006, the Swedish industrialist Bo Håkansson acquired the majority of the shares in Genovis AB. During 2007, European Institute of Science AB gradually sold out its share in Genovis AB in order to focus on new innovation challenges. Click here to visit the Genovis homepage.

The shares (EURI B) of European Institute of Science AB are traded on the market place AktieTorget.

European Institute of Science AB (Org. No. 556404-2769) applies the Swedish Code of Corporate Governance ("the Code") as of February 1, 2010. The Code complements the external rules which affect the Corporate Governance, which is constituted mainly by the Companies Act, Accountancy legislation and current listing agreement. European Institute of Science applies fiscal financial year 1 Jan – 31 Dec, and will account for any deviations from the Code in a Corporate Governance report which will be attached to the Annual Report.These documents are available for downloading:

Documents

Protokoll årsstämmor/Minutes from Annual General Meetings

(in Swedish)

Auditors (Revisorer)

  • Annika Larsson, Mazars SET Revisionsbyrå AB
  • Anders OPersson/ Mazars SET Revisionsbyrå AB (suppleant)

(In swedish only)

2017 Q1 Q2 Q3
2016 Q1 Q2 Q3 Q4 Year
2015 Q1 Q2 Q3 Q4 Year
2014 Q1 Q2 Q3 Q4 Year
2013 Q1 Q2 Q3 Q4 Year
2012 Q1 Q2 Q3 Q4 Year
2011 Q1 Q2 Q3 Q4 Year
2010 Q1 Q2 Q3 Q4 Year
2009 Q1 Q2 Q3 Q4 Year
2008 Q1 Q2 Q3 Q4 Year
2007 Q1 Q2 Q3 Q4 Year
2006 Q1 Q2 Q3 Q4 Year
2005 Q1 Q2 Q3 Q4 Year
2004 Q1 Q2 Q3 Q4 Year
2003 Q1 Q2 Q3 Q4 Year
2002 N/A N/A Q3 Q4 Year
Sign up to receive our press-releases (in swedish only) »
  • November 30, 2016 - Valberedning och Årsstämma 2017
  • November 30, 2016 - Delårsrapport 2016-01-01 till 2016-09-30
  • October 25, 2016 - EURIS senarelägger publicering av delårsrapport (Q1-3) 2016
  • August 31, 2016 - Halvårsrapport 2016-01-01 till 2016-06-30
  • August 17, 2016 - Sista dag för handel med BTA
  • Juli 5, 2016 - Utfall nyemission
  • Juni 27, 2016 - European Institute of Science får exklusiv distributionsrätt i Sverige, Danmark och Norge genom avtal med ScheBo Biotech AG
  • Juni 21, 2016 - Bolaget har erhållit sin andra order för sitt nya patientnära veterinärdiagnostiska system av nyutnämnd distributör i Litauen
  • Juni 14, 2016 - Bolaget har erhållit sin första order för sitt nya patientnära veterinärdiagnostiska system
  • Juni 7, 2016 - Publicering av Emissionsmemorandum
  • Juni 3, 2016 - Kommuniké från extra bolagsstämman 2016-06-03
  • Juni 1, 2016 - Bolagets tecknar sitt första distributionsavtal inom veterinärdiagnostik med distributör i Taiwan
  • Maj 13, 2016 - Förslag till dagordning och beslut på extra bolagsstämma 2016-06-03
  • Maj 3, 2016 - Kallelse till extra bolagsstämma den 3:e juni 2016
  • April 29, 2016 - Delårsrapport 2016-01-01 till 2016-03-31
  • Mars 22, 2016 - European Institute of Science öppnar Webbshop för global direktförsäljning av bolagets veterinära produkter
  • Mars 11, 2016 - Dagordning/förslag inför årsstämma 2016
  • Mars 4, 2016 - Bolagets instrument för veterinärdiagnostik erhåller viktig EMC CE märkning enligt EN 61326-1: 2012 och EN 61326-2-3: 2012
  • February 24, 2016 - Kallelse till årsstämma den 1:e april 2016
  • February 19, 2016 - Bolaget öppnar ett nytt laboratorium på IDEON
  • February 1, 2016 - Distributionsavtal tecknat med Primer Design Ltd
  • January 29, 2016 - Bokslutskommuniké 2015-01-01 till 2015-12-31

Contact

European Institute of Science

Scheelevägen 27, 4th floor
SE-223 70 Lund, Sweden

Tel: +46 46 286 22 30
Fax: +46 46 12 98 79

info@euris.org
www.euris.org